All In Biotech

Drug Trial Radar · NCT05279417

ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)

Phase 2b, Randomized, Multicenter, Double-blind, Parallel Group, Placebo Controlled, Dose Ranging Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to MTX Alone

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 251 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

251

Actual

Start

Feb 1, 2022

Primary completion

Sep 5, 2023

Study completion Oct 11, 2023

Sponsor

Lead sponsor
Aclaris Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates ATI-450 plus MTX versus placebo plus MTX in participants with moderate to severe active RA who have had an inadequate response to MTX alone.

Conditions

  • Rheumatoid Arthritis

Interventions

  • ATI-450 50 mg oral tablet BIDDrug

    Oral, small molecule MK2 inhibitor

  • Placebo oral tabletDrug

    Placebo tablet manufactured to match ATI-450 in appearance

  • MethotrexateDrug

    15 mg to 25 mg weekly

  • ATI-450 20 mg oral tablet BIDDrug

    Oral, small molecule MK2 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving ACR20 at Week 12Time frame: Week 12

Locations

50 sites in 4 countries. Site status is shown where the registry gives one.

  • Aclaris Investigational Site

    El Cajon, California

  • Aclaris Investigational Site

    Encino, California

  • Aclaris Investigational Site

    La Jolla, California

  • Aclaris Investigational Site

    Palm Desert, California

  • Aclaris Investigational Site

    Tampa, Florida

  • Aclaris Investigational Site

    Oklahoma City, Oklahoma

  • Aclaris Investigational Site

    Duncansville, Pennsylvania

  • Aclaris Investigational Site

    Jackson, Tennessee

  • Aclaris Investigational Site

    Cypress, Texas

  • Aclaris Investigational Site

    Mesquite, Texas

  • Aclaris Investigational Site

    San Antonio, Texas

  • Aclaris Investigational Site

    Pleven, Bulgaria

  • Aclaris Investigational Site

    Plovdiv, Bulgaria

  • Aclaris Investigational Site

    Plovdiv, Bulgaria

  • Aclaris Investigational Site

    Plovdiv, Bulgaria

  • Aclaris Investigational Site

    Plovdiv, Bulgaria

  • Aclaris Investigational Site

    Sofia, Bulgaria

  • Aclaris Investigational Site

    Sofia, Bulgaria

  • Aclaris Investigational Site

    Sofia, Bulgaria

  • Aclaris Investigational Site

    Varna, Bulgaria

  • Aclaris Investigational Site

    Brno, Czechia

  • Aclaris Investigational Site

    Hlučín, Czechia

  • Aclaris Investigational Site

    Ostrava, Czechia

  • Aclaris Investigational Site

    Pardubice, Czechia

  • Aclaris Investigational Site

    Prague, Czechia

  • Aclaris Investigational Site

    Prague, Czechia

  • Aclaris Investigational Site

    Uherské Hradiště, Czechia

  • Aclaris Investigational Site

    Bialystok, Poland

  • Aclaris Investigational Site

    Bialystok, Poland

  • Aclaris Investigational Site

    Dąbrówka, Poland

  • Aclaris Investigational Site

    Krakow, Poland

  • Aclaris Investigational Site

    Lublin, Poland

  • Aclaris Investigational Site

    Nowa Sól, Poland

  • Aclaris Investigational Site

    Poznan, Poland

  • Aclaris Investigational Site

    Poznan, Poland

  • Aclaris Investigational Site

    Poznan, Poland

  • Aclaris Investigational Site

    Sochaczew, Poland

  • Aclaris Investigational Site

    Torun, Poland

  • Aclaris Investigational Site

    Warsaw, Poland

  • Aclaris Investigational Site

    Wroclaw, Poland

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.